Table 5

Incremental cost-effectiveness ratio (ICER) for sensitivity analyses
Parameter Routine vaccination Routine and a catch-up vaccination
US$ per QALYs US$ per QALYs
Base case 219 450
Cost per year of life saved (no quality of life adjustments) 253 503
HPV16/18-related cervical diseases only 448 698
Duration of vaccine protection = 20 years Dominated1 656
Vaccine coverage= 50% for routine and 60% for catch-up 106 250
Vaccine coverage= 95% for routine and 98% for catch-up 258 425
High cost of vaccine series (increased by 25%) 406 686
High cost of treating HPV-related disease (increased by 25%) 86 326
Low cost of treating HPV-related disease (decreased by 25%) 350 573
Discounted at 0% Cost saving Cost saving
Discounted at 5% 900 1201
Pessimistic scenario2 Dominated1 998

1 A strategy is “weakly” dominated if a more effective strategy has a lower incremental cost-effectiveness ratio.

2 Pessimistic scenario assumes low HPV-related disease cost (decreased by 25%), 20 years of vaccine protection, and high health utilities (0.97 for HPV-related disease).

Kawai et al.

Kawai et al. BMC Infectious Diseases 2012 12:250   doi:10.1186/1471-2334-12-250

Open Data